Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT02941601 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02941601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02941601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2016
Completion date
February 28, 2019
Enrollment
0 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced squamous non-small cell lung cancer, metastatic squamous non-small cell lung cancer